Endpoints News 9. Apr. 2026 Roche dips into DACs with existing partner C4 Therapeutics for $20M upfront
Endpoints News 20. März 2026 Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trial
Endpoints News 9. Feb. 2026 #ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%
Endpoints News 8. Jan. 2026 Ollin’s drug clears retinal disease better than Roche’s Vabysmo in Phase 1b trial
Endpoints News 8. Jan. 2026 Charles Fuchs leaves Roche to steer ADC pipeline at Tubulis shortly after $401M Series C
Endpoints News 8. Jan. 2026 Former Genentech leaders’ protein degrader startup EpiBiologics nets $107M
Endpoints News 10. Dez. 2025 #SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%
Endpoints News 4. Dez. 2025 Clinical trials tech startup Paradigm raises $78M, acquires part of Roche’s Flatiron